Evidence map›Paper›PMID 33391003›Full record

ArticleFrontiers in physiology2020

Nestin Promotes Peritoneal Fibrosis by Protecting HIF1-α From Proteasomal Degradation.

Yangping Shentu, Huanchang Jiang, Xiaoyuan Liu, Hao Chen, Dicheng Yang, Jinqi Zhang, Chen Cheng, Yulin Zheng, Yang Zhang, Chaosheng Chen and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Yangping ShentuDepartment of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Huanchang JiangDepartment of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Xiaoyuan LiuDepartment of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Hao ChenDepartment of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Dicheng YangDepartment of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Jinqi ZhangGuanghua School of Stomatology, Sun Yat-sen University, Guangzhou, China.
Chen ChengDepartment of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Yulin ZhengDepartment of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Yang ZhangDepartment of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Chaosheng ChenDepartment of Nephrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Chenfei ZhengDepartment of Nephrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Ying ZhouDepartment of Nephrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
First Affiliated Hospital of Wenzhou Medical University · CNWenzhou Medical University · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPeritoneal dialysis (PD) is a treatment for end stage renal disease patients, but it can also cause peritoneal fibrosis. Nestin is known as a neural stem cell marker and it has many functions. The hypoxia induced factor (HIF) signaling pathway can be activated under hypoxia conditions, leading to the overexpression of some angiogenesis related genes. The aim of our study is to demonstrate Nestin's role in the development of peritoneal fibrosis (PF), and to provide a new target (Nestin) to treat PF.

methodsPD mice models were constructed by an intraperitoneal administration of PDS at 10 ml/100g/d for 4 weeks. Nestin-positive cells were isolated from peritonea of Nestin-GFP mice by flow cytometry. The relationship of Nestin and HIF1-α-VEGFA pathway was detected by Nestin knockdown, Co-immunoprecipitation and immunofluorescence. Also, proteasomal activity was demonstrated by CHX and MG132 application, followed by Western blotting and Co-immunoprecipitation.

resultsIn our experiments, we found that Nestin expression resulted in PF. Also, HIF1-α/VEGFA pathway was activated in PF. Nestin knockdown reduced the level of HIF1-α. Nestin directly bound to HIF1-α and protected HIF1-α from proteasomal degradation. Overexpression of HIF1-α reverts the fibrosis levels in Nestin-knockdown cells. In brief, Nestin inhibited the degradation of HIF1-α by mitigating its ubiquitination level, leading to the activation of HIF1-α signaling pathway, and eventually promoted PF.

conclusionWe found a novel mechanism of PF that Nestin promotes by protecting HIF1-α from proteasomal degradation. Taken together, our key findings highlight a novel mechanism by which the silencing of Nestin hinders HIF1- α -induced PF.

Indexed as

angiogenesisHIF1-α pathwaynestinperitoneal dialysisperitoneal fibrosis

Identifiers

PMID33391003
PMCPMC7772359
OpenAlexW3112657741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.